TriSalus Life Sciences announced the publication of research titled 'Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model' in the peer-reviewed Journal of Vascular and Interventional Radiology. The study, conducted in a transgenic tumor model, highlighted the superior performance of the TriNav Infusion System in delivering Embospheres into liver tumors compared to a traditional microcatheter.
Key findings from the study demonstrated that PEDD achieved a 227% increase (p=0.029) in the concentration of fluorescently labeled Embospheres within tumor tissue. Furthermore, the tumor-to-normal (T:N) ratio improved from 2.7 for a traditional microcatheter to 4.2 when delivered by PEDD, indicating more precise tumor targeting and reduced off-target delivery.
The research also showed a 209% increase (p=0.045) in delivery to peritumoral regions, demonstrating PEDD's ability to overcome challenging tumor-associated microenvironments. These results add to the growing body of evidence supporting PEDD's capability to improve the delivery of therapeutic agents for patients with primary and metastatic liver cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.